These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1686430)

  • 1. [Use of polymerase chain reaction (PCR) as an additional diagnostic method in gynecologic oncology].
    Czerwenka KF; Zeillinger R; Kury F; Manavi M; Speiser P; Peschke M; Steinhart U; Hosmann JW; Kubista E
    Gynakol Rundsch; 1991; 31 Suppl 2():378-9. PubMed ID: 1686430
    [No Abstract]   [Full Text] [Related]  

  • 2. [C-erbB-2 oncogene amplification in breast cancer in correlation to steroid and epidermal growth factor receptor].
    Manavi M; Czerwenka KF; Zeillinger R; Speiser P; Kury F; Steinhart U; Peschke M; Kubista E; Reinold E
    Zentralbl Gynakol; 1992; 114(2):82-5. PubMed ID: 1350129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luminal B breast tumors are not HER2 positive.
    Bhargava R; Dabbs DJ
    Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
    [No Abstract]   [Full Text] [Related]  

  • 4. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.
    Rosser RJ
    Cancer; 2003 Sep; 98(5):1102-3; author reply 1103. PubMed ID: 12942582
    [No Abstract]   [Full Text] [Related]  

  • 5. Altered gene expression in drug-resistant human breast cancer cells.
    Wosikowski K; Schuurhuis D; Kops GJ; Saceda M; Bates SE
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2405-14. PubMed ID: 9815641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cell receptors and proliferation markers in breast cancer].
    Czerwenka KF; Schön HJ; Zeillinger R; Kubista E; Spona J
    Gynakol Rundsch; 1989; 29 Suppl 2():400-1. PubMed ID: 2558992
    [No Abstract]   [Full Text] [Related]  

  • 7. [The effect of transport conditions on biochemically and immunohistochemically determined steroid hormone receptor content in breast cancer].
    Remmele W; Schicketanz KH
    Pathologe; 1993 Jan; 14(1):21-4. PubMed ID: 8383846
    [No Abstract]   [Full Text] [Related]  

  • 8. Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma.
    Heintz NH; Leslie KO; Rogers LA; Howard PL
    Arch Pathol Lab Med; 1990 Feb; 114(2):160-3. PubMed ID: 1967929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
    Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
    Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ductal carcinoma in situ: steroid receptors and proliferation kinetics].
    Ronay G; Sponsel N; Tulusan AH
    Pathologe; 1990 Nov; 11(6):327-31. PubMed ID: 1963219
    [No Abstract]   [Full Text] [Related]  

  • 11. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Incidence of amplification of the C-erb B2/Her-2/neu gene in human breast cancer].
    Sellami M; Gamoudi M; Krichen K; Kharrat A; Ben Romdhane K; Maalej M
    Arch Inst Pasteur Tunis; 1991; 68(1-2):33-41. PubMed ID: 1687309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer.
    Le Roy X; Escot C; Brouillet JP; Theillet C; Maudelonde T; Simony-Lafontaine J; Pujol H; Rochefort H
    Oncogene; 1991 Mar; 6(3):431-7. PubMed ID: 1707153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the c-erbB-2 gene product as detected in cytologic aspirates in breast cancer.
    Allan SM; Fernando IN; Sandle J; Trott PA
    Acta Cytol; 1993; 37(6):981-2. PubMed ID: 7902634
    [No Abstract]   [Full Text] [Related]  

  • 15. Correlation between the expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas.
    Zhang GJ; Kimijima I; Abe R; Kanno M; Katagata N; Hara K; Watanabe T; Tsuchiya A
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2329-35. PubMed ID: 9815631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.
    Rodrigues NA; Dillon D; Carter D; Parisot N; Haffty BG
    Cancer; 2003 Mar; 97(6):1393-403. PubMed ID: 12627502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Problems and solutions in the evaluation of hormone receptors in breast cancer.
    Allred DC
    J Clin Oncol; 2008 May; 26(15):2433-5. PubMed ID: 18487563
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors.
    Erdogan S; Ergin M; Tuncer I
    Neoplasma; 2003; 50(5):326-30. PubMed ID: 14628084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogene patterns in breast and ovarian carcinomas.
    Csókay B; Papp J; Besznyák I; Bösze P; Sárosi Z; Tóth J; Zalay Z; Oláh E
    Eur J Surg Oncol; 1993 Dec; 19(6):593-9. PubMed ID: 7903645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.